Literature DB >> 7511675

Structure and function of decay accelerating factor CD55.

A Nicholson-Weller1, C E Wang.   

Abstract

Studies of decay-accelerating factor (DAF) function and structure are reviewed. DAF was first recognized as a species restricting factor operating at the level of C3/C5 activation. Cloning of the gene indicates that DAF has four short consensus repeats of the type characteristic of the regulators of complement activation gene cluster family. The third short consensus repeat is responsible for DAF's complement regulatory activity and signaling. DAF, like other glycophosphatidylinositol (GPI) anchored proteins, is associated with tyrosine kinases, and these kinases are probably the signaling devices. The details of how DAF's GPI anchor in the outer leaflet of plasma membrane connects with the tyrosine kinases on the inner leaflet are not known. Although DAF does not have an essential role in controlling hemolysis of erythrocytes, it does have important role in regulating the deposition of C3 on nucleated cells. The therapeutic potential of DAF is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511675

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  49 in total

1.  Polarized entry of uropathogenic Afa/Dr diffusely adhering Escherichia coli strain IH11128 into human epithelial cells: evidence for alpha5beta1 integrin recognition and subsequent internalization through a pathway involving caveolae and dynamic unstable microtubules.

Authors:  J Guignot; M F Bernet-Camard; C Poüs; L Plançon; C Le Bouguenec; A L Servin
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  The major structural subunits of Dr and F1845 fimbriae are adhesins.

Authors:  Cristina P Van Loy; Evgeni V Sokurenko; Steve L Moseley
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Monocyte-bound monoclonal antibodies inhibit the Fc gamma RI-mediated phagocytosis of sensitized red cells: the efficiency and mechanism of inhibition are determined by the nature of the antigen.

Authors:  S L Shepard; A G Hadley
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  CD55 expression patterns on intestinal neuronal tissue are divergent from the brain.

Authors:  K A Gelderman; H J M A A Zijlmans; M J Vonk; A Gorter
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

5.  Widespread balancing selection and pathogen-driven selection at blood group antigen genes.

Authors:  Matteo Fumagalli; Rachele Cagliani; Uberto Pozzoli; Stefania Riva; Giacomo P Comi; Giorgia Menozzi; Nereo Bresolin; Manuela Sironi
Journal:  Genome Res       Date:  2008-11-07       Impact factor: 9.043

6.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM.

Authors:  R C Savani; C Wang; B Yang; S Zhang; M G Kinsella; T N Wight; R Stern; D M Nance; E A Turley
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

8.  Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.

Authors:  D R Shafren; R C Bates; M V Agrez; R L Herd; G F Burns; R D Barry
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

Review 9.  Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.

Authors:  Tolulase Olutogun; Ilaria Cutini; Rosario Notaro; Lucio Luzzatto
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443

10.  Piracy of decay-accelerating factor (CD55) signal transduction by the diffusely adhering strain Escherichia coli C1845 promotes cytoskeletal F-actin rearrangements in cultured human intestinal INT407 cells.

Authors:  I Peiffer; A L Servin; M F Bernet-Camard
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.